Real-world clinical adverse events (AEs) among nonmetastatic castration-resistant prostate cancer (nmCRPC) patients treated with novel anti-androgen (AA) therapies: A retrospective database study.

e18675Background: Novel AA agents, such aspalutamide (Apa), enzalutamide (Enza) and darolutamide (Daro) are approved for the treatment of nmCRPC. In clinical trials, they were associated with AEs s...